Aviceda Therapeutics
Aviceda Therapeutics is a clinical-stage biotech company developing next-generation immunomodulators using a proprietary HALOS™ nanotechnology platform to treat chronic inflammation. Their lead product, AVD-104, targets geographic atrophy, a vision-threatening condition, through a dual mechanism of action. The company aims to provide improved treatment options with enhanced efficacy and safety.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $207.5M
Date: 07-Jan-2025
Investors: Omega Funds, TCGX, Enavate Sciences, Jeito Capital, Longitude Capital, Blue Owl Healthcare Opportunities, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed by abrdn Inc., Digitalis Ventures
Markets: Biotechnology, Ophthalmology, Healthcare
HQ: Cambridge, Massachusetts, United States
Founded: 2018
Website: https://www.avicedarx.com/
LinkedIn: https://www.linkedin.com/company/aviceda-therapeutics/
Twitter: https://twitter.com/avicedarx
Crunchbase: https://www.crunchbase.com/organization/aviceda-therapeutics
Leave a Comment
Comments
No comments yet.